Live Breaking News & Updates on Long Term Safety Phase

Stay updated with breaking news from Long term safety phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY® injection

Presentation highlights include data for. ....

United States , Eric Hughes , Teva Pharmaceuticals , Mental Health Services Administration , Psych Congress On , Teva Neuroscience Inc , National Alliance On Mental Illness , Drug Administration , Teva Pharmaceutical Industries Ltd , National Pregnancy Registry For Atypical Antipsychotics , Teva Pharmaceutical Industries , Psych Congress , Executive Vice President , Chief Medical Officer , Clinician Factors , Defeating Barriers , Tardive Dyskinesia , Treatment Patterns , Deutetrabenazine When Initiated Using , Week Patient Titration Kit , Interim Results , Real World Effectiveness , Population Estimate , Patients With Tardive Dyskinesia , Real World Clinical Practice , Real World Antipsychotic ,